Related Experiment Video
Updated: Mar 20, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.8K
Emerging therapeutics and relevant targets for chronic Hepatitis B
1Division of Hepatology, Department of Internal Medicine, Dankook University College of Medicine, Dankook University Hospital, Cheonan, Republic of Korea. ihsong21@dankook.ac.kr.
Summary
New hepatitis B virus (HBV) treatments aim for complete eradication and immunity. Emerging therapies target viral replication, RNA interference, and immune responses to improve outcomes for chronic hepatitis B patients.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B virus (HBV) infection poses a global health challenge, necessitating complete viral eradication and immunity for effective liver disease prevention.
- Current treatments like interferon-alpha and nucleos(t)ide analogs improve responses but fall short of eliminating HBV DNA/cccDNA and achieving HBsAg seroconversion.
Purpose of the Study:
- To review emerging therapeutics and novel targets for managing chronic hepatitis B.
- To discuss advancements in HBV treatment strategies beyond current standards of care.
Main Methods:
- Literature review of preclinical and clinical investigations.
- Analysis of recently introduced therapeutic targets and anti-HBV agents.
- Discussion of HBV replication cycle-related, RNA interference-based, and immune-mediated approaches.
Main Results:
- Emerging therapeutics show promise in preclinical and clinical investigations.
- Novel targets include viral replication mechanisms, RNA interference pathways, and host immune modulation.
- Significant progress is being made in developing new agents to address unmet needs in chronic hepatitis B management.
Conclusions:
- Despite advances, current therapies do not achieve complete HBV eradication or HBsAg seroconversion.
- Emerging therapeutic strategies offer new hope for improved outcomes in chronic hepatitis B.
- Continued research into novel targets and agents is crucial for advancing hepatitis B treatment.
Related Concept Videos
01:25Hepatitis
7
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
7
01:26Targets for Drug Action: Overview
11.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.1K
01:30Inhibitors of Viral Protein Synthesis
1
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
1
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
329
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
329
01:29Pharmacogenomics: Identification of New Drug Targets
75
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
75